Clinical trial
Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase II Clinical Trial
NCT04756323 is registered in ClinicalTrials.gov with Beijing Minhai Biotechnology Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase II Clinical Trial
- Lead sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- October 27, 2020
- Completion date
- February 28, 2022
- Enrollment
- 1,000 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.